Evaluating Cystatin C for Early Detection of Contrast-Induced Acute Kidney Injury in Adults with Chronic Kidney Disease

What this Trial Is About

Researchers are evaluating the use of serum cystatin C to detect acute kidney injury AKI early, particularly when caused by contrast media used during imaging procedures. The study also aims to compare how patient characteristics affect kidney function estimates using cystatin C versus creatinine. This observational study focuses on inpatients with chronic kidney disease undergoing CT imaging or coronary angiography with contrast. Participants in this study are adults aged 18 and older who are inpatients with chronic kidney disease and scheduled for imaging involving isohexol Omnipaque contrast. Researchers will monitor kidney function before and after contrast exposure, assessing the incidence of AKI using both serum creatinine and cystatin C measurements at 24 to 48 hours and again at 7 to 10 days post-procedure. During the study, participants will have blood tests to measure kidney function markers before and after contrast administration. The main outcome is comparing AKI detection rates using creatinine versus cystatin C. Researchers will also evaluate changes in estimated glomerular filtration rate eGFR based on both markers over 10 days. The study will analyze these results to determine the potential clinical value of cystatin C in early AKI detection.

Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury